AIM's Serum-Free Iterative Rabies Vaccine Receives Acceptance for Market Registration; Institutions Predict Significant Valuation Recovery Potential for the Company
HONG KONG, April 8, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, announced on April 7, 2025 that the company's research and development of the serum-free iterative rabies vaccine has received an "Acceptance...